Lead Product(s) : Vemurafenib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Collaboration
Roche and KeChow Reach a Cooperation Agreement
Details : Under this collaboration, KeChow will promote Roche's Zelboraf® in China. Zelboraf® is an oral small molecule, selective BRAF inhibitor indicated for the treatment of patients with BRAF V600 mutation-positive advanced or inoperable melanoma.
Product Name : Zelboraf
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 20, 2021
Lead Product(s) : Vemurafenib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Atezolizumab,Cobimetinib,Vemurafenib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche's Tecentriq, on top of targeted drugs, stalls melanoma
Details : In a phase 3 study presented at the American Association for Cancer Research meeting, adding Tecentriq to the targeted melanoma drugs lowered the risk of disease progression.
Product Name : Tecentriq
Product Type : Antibody
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : Atezolizumab,Cobimetinib,Vemurafenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
